Cefazolin

Compare Cefazolin  to:
Compare
Compare

Generic Name for Cefazolin

Cefazolin (as sodium) 500mg/vial, 1g/vial; pwd for IM or IV inj or IV infusion after reconstitution and dilution; sodium content 48mg/g cefazolin.

Legal Classification:

Rx

Pharmacological Class for Cefazolin

Cephalosporin.

Manufacturer of Cefazolin

Various generic manufacturers

Indications for Cefazolin

Susceptible bacterial infections including septicemia, respiratory, biliary or GU tract, skin and skin structure, bone and joint, endocarditis. Surgical prophylaxis.

Adult dose for Cefazolin

Pneumococcal pneumonia: 500mg every 12 hours. Mild infections: 250–500mg every 8 hours; moderate to severe infections: 500mg–1g every 6–8 hours. Severe, life-threatening infections (eg, endocarditis, septicemia): 1–1.5g every 6 hours; max 12g/day. UTIs: 1g every 12 hours. Prophylaxis: see literature. Renal impairment (give initial loading dose): (CrCl 35–54mL/min): reduce dosing frequency to at least 8 hour intervals; (CrCl 11–34mL/min): reduce dose by 50%, give every 12 hours; (CrCl <10mL/min): reduce dose by 50%, give every 18–24 hours. Peritoneal dialysis: see literature.

Children's dosing for Cefazolin

<1 month: not recommended. ≥1 month: Mild to moderately severe infections: 25–50mg/kg per day in 3–4 divided doses. Severe infections: max 100mg/kg per day. Renal impairment (give initial loading dose): (CrCl 40–70mL/min): reduce dose by 40%; give every 12 hours; (CrCl 20–40mL/min): reduce dose by 75%, give every 12 hours; (CrCl 5–20mL/min): reduce dose by 90%, give every 24 hours.

Precautions for Cefazolin

Penicillin or other allergy. Renal impairment: reduce dose. GI disease (esp. colitis). Monitor PT in patients at risk (eg, renal or hepatic impairment, poor nutritional state, long term use, or anticoagulant therapy). Pregnancy (Cat.B). Nursing mothers.

Interactions for Cefazolin

Potentiated by probenecid. May cause false (+) Clinitest, Benedict's, or Fehling's soln.

Adverse Reactions for Cefazolin

GI upset, anaphylaxis, rash, pruritus, local reactions, blood dyscrasias, elevated liver enzymes.

How is Cefazolin supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.